[{"id":"076cd6de-9c13-4f66-953e-ae61920d0ae1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05911217","created_at":"2023-06-20T14:07:52.799Z","updated_at":"2024-07-02T16:35:00.806Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer","source_id_and_acronym":"NCT05911217","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e satricabtagene autoleucel (CT041)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-27"},{"id":"5d0bb067-65b0-4094-b54b-a91e3fcb9734","acronym":"CT041-CG4006","url":"https://clinicaltrials.gov/study/NCT03874897","created_at":"2021-03-09T08:59:23.397Z","updated_at":"2024-07-02T16:35:06.986Z","phase":"Phase 1","brief_title":"Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.","source_id_and_acronym":"NCT03874897 - CT041-CG4006","lead_sponsor":"Peking University","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • cyclophosphamide • satricabtagene autoleucel (CT041)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 03/26/2019","start_date":" 03/26/2019","primary_txt":" Primary completion: 03/20/2021","primary_completion_date":" 03/20/2021","study_txt":" Completion: 01/26/2024","study_completion_date":" 01/26/2024","last_update_posted":"2024-04-30"},{"id":"c23452ee-9413-4c76-bc52-df1b531d2d45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04581473","created_at":"2021-03-09T09:00:08.732Z","updated_at":"2024-07-02T16:35:16.030Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","source_id_and_acronym":"NCT04581473","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 expression • CLDN18.2 positive","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiTan (rivoceranib) • irinotecan • satricabtagene autoleucel (CT041)"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2038","study_completion_date":" 06/30/2038","last_update_posted":"2024-03-06"},{"id":"71a3a4f5-c99c-458e-aa62-fed7409bf1e8","acronym":"ELIMYN18.2","url":"https://clinicaltrials.gov/study/NCT04404595","created_at":"2021-03-09T08:59:58.909Z","updated_at":"2024-07-02T16:35:25.770Z","phase":"Phase 1/2","brief_title":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","source_id_and_acronym":"NCT04404595 - ELIMYN18.2","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e satricabtagene autoleucel (CT041)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2023-12-19"},{"id":"08310589-48de-424e-82b3-d1923ffca137","acronym":"","url":"https://clinicaltrials.gov/study/NCT03302403","created_at":"2021-01-18T16:18:51.239Z","updated_at":"2024-07-02T16:36:40.277Z","phase":"","brief_title":"Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors","source_id_and_acronym":"NCT03302403","lead_sponsor":"Kang YU","biomarkers":" CLDN18 • GPC3","pipe":" | ","alterations":" CD19 positive • GPC3 positive","tags":["CLDN18 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • satricabtagene autoleucel (CT041) • CT011 • CT0180 • CT032 • cyclophosphamide intravenous • zevorcabtagene autoleucel (CT053)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/29/2017","start_date":" 12/29/2017","primary_txt":" Primary completion: 12/12/2020","primary_completion_date":" 12/12/2020","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2020-10-08"},{"id":"9db49392-63c3-451c-aa4c-e6815cfac1d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03159819","created_at":"2021-01-19T14:12:33.040Z","updated_at":"2024-07-02T16:37:13.096Z","phase":"","brief_title":"Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03159819","lead_sponsor":"Changhai Hospital","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e satricabtagene autoleucel (CT041)"],"overall_status":"Unknown status","enrollment":" Enrollment 24","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2018-03-12"}]